Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis

Abstract Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in prom...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Reza Fadaei, Hossein Poustchi, Reza Meshkani, Nariman Moradi, Taghi Golmohammadi, Shahin Merat
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7bc83b5eb5d54df5bca1e284d6a04417
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7bc83b5eb5d54df5bca1e284d6a04417
record_format	dspace
spelling	oai:doaj.org-article:7bc83b5eb5d54df5bca1e284d6a044172021-12-02T15:08:18ZImpaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis10.1038/s41598-018-29639-52045-2322https://doaj.org/article/7bc83b5eb5d54df5bca1e284d6a044172018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-29639-5https://doaj.org/toc/2045-2322Abstract Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in promoting cholesterol efflux, which is determined by cholesterol efflux capacity (CEC). Hitherto, the role of HDL, as defined by CEC has not been assessed in NAFLD patients. In this research study, we present the results of a study of cAMP-treated J774 CEC and THP-1 macrophage CEC in ApoB-depleted plasma of 55 newly diagnosed NAFLD patients and 30 controls. Circulating levels of ApoA-I, ApoB, preβ-HDL, plasma activity of CETP, PLTP, LCAT and carotid intima-media thickness (cIMT) were estimated. cAMP-treated J774 and THP-1 macrophage CEC were found to be significantly lower in NAFLD patients compared to controls (P < 0.001 and P = 0.003, respectively). In addition, it was discovered that both ApoA-I and preβ1-HDL were significantly lower in NAFLD patients (P < 0.001). Furthermore, cAMP-treated J774 CEC showed independent negative correlation with cIMT, as well as the presence of atherosclerotic plaque in NAFLD patients. In conclusion, our findings showed that HDL CEC was suppressed in NAFLD patients, and impaired cAMP-treated J774 CEC was an independent risk factor for subclinical atherosclerosis in NAFLD patients, suggesting that impaired HDL functions as an independent risk factor for atherosclerosis in NAFLD.Reza FadaeiHossein PoustchiReza MeshkaniNariman MoradiTaghi GolmohammadiShahin MeratNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Reza Fadaei Hossein Poustchi Reza Meshkani Nariman Moradi Taghi Golmohammadi Shahin Merat Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
description	Abstract Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in promoting cholesterol efflux, which is determined by cholesterol efflux capacity (CEC). Hitherto, the role of HDL, as defined by CEC has not been assessed in NAFLD patients. In this research study, we present the results of a study of cAMP-treated J774 CEC and THP-1 macrophage CEC in ApoB-depleted plasma of 55 newly diagnosed NAFLD patients and 30 controls. Circulating levels of ApoA-I, ApoB, preβ-HDL, plasma activity of CETP, PLTP, LCAT and carotid intima-media thickness (cIMT) were estimated. cAMP-treated J774 and THP-1 macrophage CEC were found to be significantly lower in NAFLD patients compared to controls (P < 0.001 and P = 0.003, respectively). In addition, it was discovered that both ApoA-I and preβ1-HDL were significantly lower in NAFLD patients (P < 0.001). Furthermore, cAMP-treated J774 CEC showed independent negative correlation with cIMT, as well as the presence of atherosclerotic plaque in NAFLD patients. In conclusion, our findings showed that HDL CEC was suppressed in NAFLD patients, and impaired cAMP-treated J774 CEC was an independent risk factor for subclinical atherosclerosis in NAFLD patients, suggesting that impaired HDL functions as an independent risk factor for atherosclerosis in NAFLD.
format	article
author	Reza Fadaei Hossein Poustchi Reza Meshkani Nariman Moradi Taghi Golmohammadi Shahin Merat
author_facet	Reza Fadaei Hossein Poustchi Reza Meshkani Nariman Moradi Taghi Golmohammadi Shahin Merat
author_sort	Reza Fadaei
title	Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
title_short	Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
title_full	Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
title_fullStr	Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
title_full_unstemmed	Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
title_sort	impaired hdl cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/7bc83b5eb5d54df5bca1e284d6a04417
work_keys_str_mv	AT rezafadaei impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT hosseinpoustchi impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT rezameshkani impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT narimanmoradi impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT taghigolmohammadi impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT shahinmerat impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis
_version_	1718388196144840704

Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis

Ejemplares similares